Literature DB >> 2449506

Vancomycin and the red-man syndrome: pharmacodynamics of histamine release.

R E Polk1, D P Healy, L B Schwartz, D T Rock, M L Garson, K Roller.   

Abstract

Two regimens for infusing vancomycin over 1 h (500 mg every 6 h for five doses or 100 mg every 12 h for three doses) were used in 11 volunteers. Subjects received both regimens one week apart; the regimen used first for each subject was randomized. Nine receiving the 1000-mg dose experienced the "red-man (neck)" syndrome; none had the reaction while receiving the 500-mg dose (P = .002). Plasma histamine concentration, measured every 10 min during the first infusion of each regimen, increased in most subjects given 1000-mg doses; there was only a slight change in histamine levels after 500-mg doses. There was a significant relation between histamine release and reaction severity; frequency and severity of the reaction declined with subsequent doses. We conclude that the red-man syndrome occurs frequently in normal adults who receive 1000 mg of vancomycin over 1 h, that vancomycin causes an infusion rate-dependent increase in plasma histamine concentration, and that the increase in plasma histamine concentration is correlated with the severity of the reaction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2449506     DOI: 10.1093/infdis/157.3.502

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  35 in total

Review 1.  Pediatric antibiotic therapy in 1990s.

Authors:  S Chaudhary
Journal:  Indian J Pediatr       Date:  1995 Jan-Feb       Impact factor: 1.967

2.  Vancomycin-induced red man syndrome in pediatric oncology: still an issue?

Authors:  Tiene Bauters; Barbara Claus; Petra Schelstraete; Hugo Robays; Yves Benoit; Catharina Dhooge
Journal:  Int J Clin Pharm       Date:  2011-12-13

3.  A clinical view of vancomycin in 1990.

Authors:  W T Siebert
Journal:  Tex Heart Inst J       Date:  1990

Review 4.  Safety considerations in the use of drug combinations during general anaesthesia.

Authors:  E S Ransom; R A Mueller
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

5.  Immune-mediated reactions to vancomycin: A systematic case review and analysis.

Authors:  Jasmit S Minhas; Paige G Wickner; Aidan A Long; Aleena Banerji; Kimberly G Blumenthal
Journal:  Ann Allergy Asthma Immunol       Date:  2016-05-04       Impact factor: 6.347

Review 6.  Pharmacokinetic optimisation of vancomycin therapy.

Authors:  W G Leader; M H Chandler; M Castiglia
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

7.  Beta-lactam antibiotic sensitization and its relationship to allergic diseases in tertiary hospital nurses.

Authors:  Inseon S Choi; Eui-Ryoung Han; Seong-Wook Lim; Seong-Ryoon Lim; Ji-Na Kim; Sin-Young Park; Su-Kyoung Chae; Hye-Hyeun Lim; Young-Ae Seol; You-In Bae; Young-Ho Won
Journal:  Allergy Asthma Immunol Res       Date:  2010-03-24       Impact factor: 5.764

8.  Absence of "red man syndrome" in patients being treated with vancomycin or high-dose teicoplanin.

Authors:  M J Rybak; E M Bailey; L H Warbasse
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

9.  Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections.

Authors:  J K James; S M Palmer; D P Levine; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

10.  Comparative prophylactic efficacies of ciprofloxacin, ofloxacin, cefazolin, and vancomycin in experimental model of staphylococcal wound infection.

Authors:  D S Kernodle; A B Kaiser
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.